Thanks for this Galileo,
I extracted the severe entries from the data, which mostly pertained for the short-term, to neurological events (Bell's Palsy, Memory or Hearing Loss, etc.), since myocarditis is often diagnosed much later than the window of the study. I then compared that 'severe' group to the severe events reported in the US VAERS database, extracted 5 Feb 2022.
If this is comparative, and I am sure that I am under-estimating this by several shortfalls in specific AE's (death, myocarditis, stroke, etc.), then the US VAERS database is under-reporting severe adverse events, by a factor of 30 to 1 on these AE's alone.
EVG
TES :-)